Mass balance and pharmacokinetic characterization of zavegepant in healthy male subjects

Documenti analoghi

• No clinically relevant electrocardiogram effects in a randomized TQT study of single therapeutic/supratherapeutic rimegepant doses in healthy adults
  di: Rajinder Bhardwaj, et al.
  Pubblicazione: (2024)
• Safety, tolerability, and pharmacokinetics of single and multiple ascending doses of zavegepant nasal spray in healthy adults from two phase 1 randomized, placebo‐controlled trials
  di: Richard Bertz, et al.
  Pubblicazione: (2025)
• Assessment of pharmacokinetic and pharmacodynamic interactions between zavegepant and sumatriptan: A phase 1, randomized, placebo‐controlled study in healthy adults
  di: Rajinder Bhardwaj, et al.
  Pubblicazione: (2024)
• Effects of multiple‐dose administration of zavegepant nasal spray on the single‐dose pharmacokinetics of ethinyl estradiol‐levonorgestrel
  di: Rajinder Bhardwaj, et al.
  Pubblicazione: (2024)
• Concentration‐QTc and cardiac safety analysis of single and multiple zavegepant nasal spray doses in healthy participants to support approval
  di: Jim H. Hughes, et al.
  Pubblicazione: (2024)